Delivery Order SPE2DB24D2003-SPE2DB25FXMN6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (16-count) with a ceiling value of $1,375.92. This is a firm fixed price delivery order with no set-aside designation, issued under the agency's competitive procurement processes. The order is set to be completed by August 13, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $6,244.42 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablet unit dose packages (16 count) on September 8, 2025, with completion expected by September 9, 2025. This competitively awarded, firm fixed-price delivery order represents a continuation of the company's pharmaceutical supply support to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $2,850.02 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (16 count). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is scheduled for ultimate completion on August 28, 2025, with performance taking place at the vendor's corporate office in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $29,146.75 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16-count unit dose packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting AmerisourceBergen's role as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of UBRELVY 100 mg tablets (16 unit dose packaging) with a ceiling value of $9,128.76. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was competitively procured with no set-aside...
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB24D2003Indefinite Delivery Contract
- SPE2DB24D2003-SPE2DB25FXMN6Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order contract for UBRELVY 100 mg tablets (16-count unit dose packages) on September 9, 2025, with a contract ceiling value of $1,252.24 and ultimate completion date of September 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement. The work is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and represents a direct pharmaceutical supply need within the federal medical procurement system. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999 through December 2026. AmerisourceBergen serves as a prime pharmaceutical vendor for the Defense Logistics Agency's Medical Supply Chain, providing a comprehensive portfolio of medications, vaccines, medical devices, and specialty healthcare commodities to support military and federal healthcare systems. UBRELVY, used for migraine treatment, falls within the company's extensive therapeutic product offerings that support Defense Health Agency operations and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 9/9/25 |